{"cik":1806310,"taxonomy":"us-gaap","tag":"LongTermDebt","label":"Long-term Debt","description":"Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.","entityName":"Taysha Gene Therapies, Inc.","units":{"USD":[{"end":"2021-09-30","val":27812000,"accn":"0001564590-21-056225","fy":2021,"fp":"Q3","form":"10-Q","filed":"2021-11-10","frame":"CY2021Q3I"},{"end":"2021-12-31","val":37192000,"accn":"0001564590-22-012782","fy":2021,"fp":"FY","form":"10-K","filed":"2022-03-31","frame":"CY2021Q4I"},{"end":"2022-03-31","val":37386000,"accn":"0001564590-22-020260","fy":2022,"fp":"Q1","form":"10-Q","filed":"2022-05-16","frame":"CY2022Q1I"},{"end":"2022-06-30","val":37580000,"accn":"0001564590-22-029155","fy":2022,"fp":"Q2","form":"10-Q","filed":"2022-08-11","frame":"CY2022Q2I"},{"end":"2022-09-30","val":37773000,"accn":"0001564590-22-036936","fy":2022,"fp":"Q3","form":"10-Q","filed":"2022-11-08","frame":"CY2022Q3I"},{"end":"2022-12-31","val":37967000,"accn":"0000950170-23-010343","fy":2022,"fp":"FY","form":"10-K","filed":"2023-03-28","frame":"CY2022Q4I"},{"end":"2023-03-31","val":38161000,"accn":"0000950170-23-021333","fy":2023,"fp":"Q1","form":"10-Q","filed":"2023-05-11","frame":"CY2023Q1I"},{"end":"2023-06-30","val":38354000,"accn":"0000950170-23-042089","fy":2023,"fp":"Q2","form":"10-Q","filed":"2023-08-14","frame":"CY2023Q2I"}]}}